xMAP Multiplexing 11 - Diasorin & Luminex Support

Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world.

Nucleic acid amplification-based tests (NAATs)—such as real-time PCR and isothermal amplification—are the gold standard in molecular diagnostic technologies that are being utilized to detect SARS-CoV-2, the COVID-19 disease-causing virus.¹

There are two critical and sequential steps that must occur prior to running a SARS-CoV-2 NAAT. The first is proper sample collection per the CDC’s guidelines,² because inadequate collection may lead to inaccurate or inconclusive diagnostic results. The second is effective viral RNA extraction. The CDC has qualified and validated several extraction systems for use with their 2019-nCoV real-time RT-PCR Diagnostic Panel,³ including systems from Qiagen, Roche, and Biomerieux, but the rapid increase in testing has led to a global shortage of commercially available extraction kits. Consequently, lab test sites need to explore alternative vendors for extraction kits to qualify and validate with their respective NAAT.

Most commercial RNA extraction kits utilize similar principles for RNA extraction, with guanidine thiocyanate being the most popular chaotropic agent to lyse the virus, denature RNases, and protect RNA from degradation. These kits often include additional protocol steps, some designated as optional to improve purity, yield, or analyte detection. When selecting an RNA extraction kit, remember that SARS-CoV-2 is an RNA virus, and thus requires protection from RNases. Understanding the kit reagents and protocol will help ensure quality RNA extraction and reproducible results.

Luminex’s ARIES^® SARS-CoV-2 Assay uses a sample-to-answer PCR platform that performs nucleic acid extraction, target amplification, and detection. It is one of the commercially available NAATs on the market.

Jackie Surls, PhD, is a Development & Applications Scientist at Luminex Corporation.

References

“Coronavirus Test Tracker: Commercially Available COVID-19 Diagnostic Tests.” Genome Web (Internet). Cited Mar 2020. Available from: https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests.
“Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19).” The Centers for Disease Control and Prevention (Internet). Cited Mar 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.
“CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” The Centers for Disease Control and Prevention (Internet). Cited Mar 2020. Available from: https://www.fda.gov/media/134922/download.

Webinar: Mouse Model Analysis Is Better with Multiplexing

Query hundreds of immunoassay targets, even with limited sample volume

To make the most of immunology-focused assays using the limited tissue and fluid samples available from mouse models, scientists should consider using xMAP^® Technology from Luminex, according to Daniel Braunschweig, Proteomics Field Application Scientist Leader at Bio-Rad Laboratories.

That’s the takeaway from a 30-minute webinar hosted by Labroots, which is now available for on-demand viewing and offers continuing education credits. In the presentation, Braunschweig spoke about getting the most out of bead-based multiplexing, experimental considerations, and key attributes for multiplex assays.

Variability in Mouse Models

Mouse models represent a $2 billion industry, Braunschweig noted, in part because they’re a mainstay for pharmaceutical R&D and are accepted models even for cutting-edge treatments such as immunotherapies and cell or gene therapies. Knock-out strains and assay content are readily available. However, variety among mouse strains, experimental design, and interpretation processes can lead to inherent variability when dealing with this type of data, he added.

Generating Data with Minimal Biological Sample

Perhaps the biggest challenge in working with mouse models, though, is that tissues and fluids are precious because they’re available in such small volumes. Because of this, researchers require cost-effective platforms with high sensitivity and specificity, comprehensive results, and strong reproducibility, Braunschweig said. He noted that xMAP Technology meets all of those criteria, generating data from potentially hundreds of targets per sample, even when there’s minimal sample to use. Automated multiplexing also reduces hands-on time and minimizes variability across experiments.

The webinar also introduces viewers to key experimental considerations, such as how analyte profiles differ by mouse age or tissue type, and assay attributes, including a large dynamic range and the ability to profile entire biological pathways.

If you work with mouse models and need immunoassay data, be sure to carve out a little time for this informative webinar.

How to Choose an Assay Development Platform

The Luminex Team knows assay development. Check out some tips from our experts below.

If you need to design a new assay, there are several factors you’ll want to consider before selecting the platform you’ll develop it on. Based on our experience, these are the most important:

Analyte of interest: Is your assay meant to detect DNA, proteins, or something else? While xMAP^® Technology is flexible and allows you to detect a range of analytes, other platforms may be specific to certain sample types. Be sure to do your research before selecting the platform you’ll use for an assay.

Number of analytes: If you need a multiplex assay to detect several analytes at once, that may affect your assay optimization workflow. When sample volume is particularly low—such as with precious samples—a multiplex platform can help reduce the amount of sample required for the assay.

Sensitivity: If your target of interest requires high sensitivity, then this will have to be factored in as you design the assay. If possible, identify the relevant concentration range of your target in the matrix you are testing. This can be done by a quick literature search. Then, evaluate available technologies to best meet your specific assay needs.

Ease of use: This is a really important consideration for selecting an assay platform. How easy is it to use the instrument and to analyze the data it generates? Some platforms offer universal software to do the analysis, which might make life easier if your lab already has other instruments that also use that software. Be sure to match the platform to the skill set available.

Flexibility: Some platforms—like those offered by Luminex—offer an open-architecture design that can be configured to perform a wide variety of protein or nucleic acid assays quickly, cost-effectively, and accurately. Having the ability to build your own assays, or have an assay developer of your choosing build an assay, is key to the flexibility of your custom projects.

Reagent availability: It would be frustrating to develop your assay only to discover that you can’t run it because reagents are unavailable. Unfortunately, this is not uncommon. For some systems, reagents seem to be permanently on backorder. Check to make sure that all components of your assay are easy to acquire before you make your platform selection.

Software: If your assay will be under FDA review, then even the software you use has to be compliant. Consider a platform that offers 21 CFR Part 11-compliant software, and an instrument that is FDA-cleared.

Vendor support: You’ll want to ensure the platform you choose comes with strong technical support for both the instrument and the chemistry used in the assay. To determine this, look through online scientific forums such as those on ResearchGate, or contact authors who have published results from the platform you’re considering and ask about their experience with the vendor.

Community support: In addition to vendor support, it’s helpful to have robust literature to guide you in assay development. When you’re considering a platform, take a moment to find out whether there are sufficient publications that show validated assays. These will make a huge difference as you develop your own assay on that platform.

Resources

xMAP^® Cookbook to Design Your Own Assays [Download]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]
Getting Started with xMAP^® Technology [Video]
View the latest xMAP^® Insights Newsletter[Online & Download]

3D Organoid Cultures Offer Clues to Heterogeneous Therapy Response in Cancer Patients

Luminex-powered DigiWest^® assays show significant intratumoral differences in response

A publication in PLoS Genetics sheds much-needed light on the heterogeneity of drug response within tumors. The scientists used organoid cultures with several analytical tools, including DigiWest protein expression assays, which are based on xMAP^® Technology from Luminex.

“Heterogeneous pathway activation and drug response modeled in colorectal-tumor-derived 3D cultures” comes from lead author Dirk Schumacher, senior author Christian Regenbrecht, and collaborators at several institutions in Germany and the U.S. The team aimed to characterize how organoid cultures — 3D cell cultures derived from patient tumor samples — could be used to understand heterogeneity of therapeutic response within an individual patient. Because organoids represent multiple cell populations from a tumor, they were expected to offer a more accurate reflection of biological response to treatment than simpler assessments, such as those based on a single genetic variant.

“The heterogeneity of tumors remains a severe obstacle in routinely translating preclinical data to patient treatments,” the scientists note in the paper. “While the organoid cultures largely recapitulated the genomic profiles of donor tumors, the overall treatment responses and inhibitory effects on the intracellular signaling system were quite variable.” Indeed, sampling multiple regions from the same organoid revealed as much as a 30-fold difference in drug response metrics.

Study Methods

For the study, the team looked at organoids derived from colorectal cancer (CRC) samples and focused on characterizing the KRAS/MAPK-signaling pathway as well as treatment effects from compounds targeting the PIK3CA and RAS/MAPK pathways as well as receptor tyrosine kinases. “MAPK signaling, analyzed by targeted proteomics, shows unexpected heterogeneity irrespective of RAS mutations and is associated with variable responses to EGFR inhibition,” the team reports. “In addition, we obtained evidence for intratumoral heterogeneity in drug response among parallel ‘sibling’ 3D cultures established from a single KRAS-mutant CRC.”

Scientists generated expression data for dozens of proteins using DigiWest, a multiplex approach developed at the University of Tübingen to replace the laborious western blot. The analysis was performed with the FLEXMAP 3D^® instrument.

“Our results imply that separate testing of drug effects in multiple subpopulations may help to elucidate molecular correlates of tumor heterogeneity and to improve therapy response prediction in patients,” the team concludes.

DigiWest is a trademark of NMI registered in Germany and the EU.

Resources

MAGPIX^® Systems See New Life Through Equipment Donation Program

MilliporeSigma and Seeding Labs send gently used instruments to labs in need

Thanks to a nonprofit organization called Seeding Labs and our Licensed Technologies Partner MilliporeSigma, previously-owned xMAP^® Technology systems are helping scientists in laboratories in developing countries around the world answer important new research questions.

Seeding Labs is a Boston-based nonprofit dedicated to empowering every scientist to transform the world. They have a number of programs, including Instrumental Access, their flagship program which makes affordable, high quality lab equipment available to carefully vetted university and research institutes in developing countries.

Mike Vaughn, western regional sales manager at MilliporeSigma, has been working closely with Seeding Labs as part of his company’s partnership with the nonprofit. “We partner with Seeding Labs to advance global science. One way we are doing that is through donating used lab equipment,” he says. Seeding Labs fills up entire shipping containers of donations with much-needed equipment and consumables that are then shipped to the Instrumental Access awardees. “People say it would take 10 years to get as much equipment as they get in a single day from this donation,” he says.

Teaming up with a biotech giant like MilliporeSigma is invaluable for Seeding Labs. Vaughn and his colleagues are able to secure high-quality used instrumentation through demo programs and trade-in offers. They then repair and repack those instruments, and donate them to labs chosen by the nonprofit. We’re honored that our MAGPIX^® Systems have gotten new life through this program; Vaughn has already facilitated the donation of several of them, which found a second home at university labs in Africa, and has more in the donation pipeline. In addition to helping scientists build research infrastructure in underfunded labs, this program also helps researchers who want to upgrade their equipment without sending older systems to a landfill.

MAGPIX^® Systems are a good fit for the Seeding Labs program, according to Vaughn, because they’re simple instruments that require minimal maintenance and can be easily installed by users. Because Luminex and MilliporeSigma offer so many video tutorials for working with these systems, like on Seeding Labs’ TeleScience platform, researchers anywhere can easily get them up and running, troubleshoot basic problems, and learn to build their own multiplex assays. “It helps them get great results the first time out,” Vaughn says.

Resources

Webinar Wednesday: For Tracking Anti-Apoptosis Proteins, Scientists Turn to Multiplexing [Blog]
Luminex MAGPIX System [Video]
Luminex xMAP Technology Overview [Video]
Getting Started with xMAP Technology [Video]

METHODS Journal: A New Multiplexing Protocol Performs Protein and Gene Level Measurements on a Single Luminex Platform

Researchers demonstrate a high-throughput method for measuring mRNA and proteins using the Luminex xMAP^® Platform

You shouldn’t have to choose between analyzing gene expression or screening for proteins. In a Methods publication, researchers demonstrate how to measure mRNA expression and analyze proteins with a single sample set using Luminex xMAP^® Technology.

The article comes from lead author Damon Cook, senior author Thao Sebata, and collaborators at Thermo Fisher Scientific. While it is well-known that multi-dimensional data sets are widely valuable, the authors note that there are obstacles generating and utilizing them using conventional technology. “Bottlenecks to traditional immunoassays and gene expression assays include large sample consumption, time-consuming experimental procedures, and complex data analysis,” the team reports. A better approach—they add—would “ideally be able to work with different types of starting material, and make maximum use of often precious, difficult to obtain, and limited clinical tissue samples.”

The scientists turned to xMAP Technology for multiplex analysis of proteins and mRNA expression. “Using xMAP technology to measure secreted protein and mRNA expression levels on a Luminex instrument … overcomes previous limitations, as these assays are sensitive, specific to a target, and quality control-tested for the end-user,” they write.

For this protocol, the team paired the QuantiGene™ Human 80-plex Panel for measuring gene expression with the ProcartaPlex™ Human Immune Monitoring 65-plex Panel for analysis of corresponding proteins. The assays require a low sample volume and enable high-throughput analysis of targets. Both assays were prepared from a single sample and then run on the Luminex xMAP multiplexing platform.

“Often, measurement of mRNA expression or protein levels alone may not tell a complete story, as mRNA expression levels may not translate to protein,” the scientists note. “Our study demonstrated [that] a single sample can provide both gene expression and protein profiles.”

Resources

Advances in Bead-Based Biomarker Detection [Methods xMAP Issue]
Getting Started with xMAP^® Technology [Video]
xMAP^® Cookbook to Design Your Own Assays [Download]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]

Webinar: Fast, Economical Malaria Testing with xMAP^® Technology

Multiplex assay allows for detailed investigations of transmission and drug resistance

Multiplexing technology from Luminex has been critical for the development of assays designed to study human SNPs involved in parasite transmission as well as the spread of drug resistance markers in Plasmodium falciparum. That was a key message in this presentation from Lynn Grignard, a research fellow at the London School of Hygiene and Tropical Medicine.

Malaria, which led to 212 million cases worldwide in 2015, is caused by a parasite with a remarkably complex life cycle. Important steps include development in the mosquito and transmission to a human host when the mosquito feeds, followed by a liver cycle and blood stage within the human. While malaria is preventable and curable, Grignard said, it remains a life-threatening disease, particularly in Africa.

Developing Assays

In her presentation, Grignard focused on two areas she studies: how human SNPs are involved in transmission or protection against malaria, and how drug resistance is spread to the parasite. These investigations led to the development of two assays based on xMAP^® Technology. “You can’t take a lot of blood,” she said, “so you need to multiplex if you want to test an ever-growing number of markers.”

The first assay targets human SNPs in genes such as G6PD, HbS, and HbC. Grignard designed the assay to incorporate both genomic PCR amplification and allele-specific primer extension, and she worked with Luminex to identify the best bead sets for her targets. Genotyping results for all markers are available in six or seven hours. She reported that the biggest rewards in assay quality came from optimizing the genomic PCR process and adding BSA during the bead hybridization protocol.

Furthering Research

Grignard is already moving to the next step, which is combining the genetic data with enzyme data to correlate a specific genotype with its effect on enzyme activity. Already, she has seen cases where the genotype doesn’t adequately explain a change in enzyme activity, but that just helps her improve the multiplex assay. “You can then go back to the drawing board, and Luminex allows you to do that because you can add more SNPs to your assay,” she said.

The second assay, which is still in the final stages of optimization, tests human blood and parasite DNA to evaluate markers of drug resistance. While she plans to use the assay to track parasites transmitted from humans to mosquitoes, it could also be used to monitor drug resistance in a population, she noted.

Ultimately, Grignard concluded, xMAP Technology offers a compelling solution for fast, economical multiplex assays that require little DNA input. Results can be generated in a single working day, and the technology is robust enough to be used with blood spots stored on filter paper, making it amenable to field use in Africa.

Resources

Getting Started with xMAP^® Technology [Video]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]
xMAP^® Cookbook to Design Your Own Assays [Download]
An Expert’s Guide to Multiplexing Immunoassays [Blog]
View the xMAP^® Webinar Blog Series [Online Tool]

Webinar: Multiplex Serological Assay Developed to Identify Avian Influenza Subtypes

Rapid detection could help prevent transmission and reduce flock losses

In addition to being a public health threat, avian influenza is also costly and potentially devastating to people whose livelihoods depend on raising poultry. To enable faster detection of bird flu and identification of its subtypes, scientists at Wageningen Bioveterinary Research in The Netherlands developed a multiplex assay using xMAP^® Technology.

In this 20-minute video presentation, veterinarian Evelien Germeraad reports on the development and validation of that assay. Wageningen Bioveterinary Research, part of Wageningen University & Research, is a national reference lab for infectious animal diseases, receiving samples for testing from all over the country. The lab tests cattle, poultry, goats, and other types of animals for illnesses ranging from rabies and tularemia to psittacosis and foot-and-mouth disease. Scientists there run as many as 300,000 assays per year, of which 20,000 are deployed for avian influenza, the main focus of Germeraad’s talk.

Poultry Industry in The Netherlands

In The Netherlands, the poultry industry is valued at about €1.5 billion. The country is home to 100 million chickens, and bird flu is not uncommon. Recent outbreaks occurred in 2003, 2014, and 2016. In the 2014 outbreak, which affected just a handful of farms, nearly 250,000 chickens had to be culled to contain the pathogen. This enormous scale of loss is why it’s so important to diagnose avian influenza quickly, Germeraad says.

One of the challenges of testing for avian influenza is the broad range of subtypes. There are 16 types of hemagglutinin in birds, plus nine types of neuraminidase, making for a large number of H+N protein subtypes of the virus. Some strains have low pathogenicity, while others are so severe that mortality can rise to 100% in just a few days, Germeraad says. Conventional serological assays — such as ELISA, hemagglutination inhibition testing, and agar gel immunodiffusion — are time-consuming, require high volumes of sample, and do not all produce subtype-specific results.

For a faster test that would identify all subtypes, Germeraad and her team turned to xMAP Technology and the MAGPIX^® system. They designed a single assay with 54 beads to cover all subtypes from a small serum sample. Results come back showing median fluorescent intensity for each protein. In a validation study using 87 chicken samples, 92% of results were concordant with conventional assays. Since then, the assay has been used on hundreds of bird samples, including swans, ducks, and turkeys in addition to chickens. Going forward, Germeraad hopes to optimize the assay further to establish more accurate cut-offs and improve sensitivity.

Resources

Getting Started with xMAP^® Technology [Video]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]
xMAP^® Cookbook to Design Your Own Assays [Download]
An Expert’s Guide to Multiplexing Immunoassays [Blog]
View the xMAP^® Webinar Blog Series [Online Tool]

METHODS Special Issue: Multiplex Assays Enable Simultaneous Measurement of RNA and Proteins

A more comprehensive view sheds light on the biological response to muscle injury

Scientists at the University of North Texas have established a novel method for measuring a broad range of RNA and protein biomarkers. In their study, they employed bead-based multiplex detection to assess the effects of skeletal muscle injury over time, but the same concept could be useful for many clinical applications.

The team—led by Melody Gary—published their results in an April 2019 issue of Methods.

Multiplex methods can do more with less

For this project, they used a multiplex assay based on xMAP^® Technology to assess the injury response. “A current weakness of research…is the failure to include a large enough pool of biomarkers from a variety of types (i.e., lncRNA, mRNA, and protein),” the scientists note. “Our laboratory proposes to address known limitations by employing multiplex assay design to reduce sample volume, increase throughput, and reduce experimental cost compared to running singleplex assays.”

In this study, subjects ran a half-marathon and blood samples were drawn 4 and 24 hours after the event. Thanks to multiplex technology, the team was able to quantify 90 different targets, including “mRNA, lncRNA, cytokines, soluble cytokine receptors, and myokines.” One of the goals of this work was to distinguish biomarkers representative of the initial response, a delayed response, and a prolonged response—that is, biomarkers seen at both the 4-hour and the 24-hour marks.

The project provided results on injury responders, including many mRNAs, lncRNAs, cytokines, and myokines that had elevated levels in the short-term or longer-term following injury, or were consistently elevated at both readings. “These findings demonstrate the interplay between RNA and protein biomarkers in response to skeletal muscle injury,” the researchers write. “The roles of lncRNA in skeletal muscle-related injury are still emerging, but based on our observations, it is reasonable to speculate that they have effects beyond the regulation of NF-kB signaling.”

“This novel, experimental application of bead-based multiplexing is applicable to a variety of clinical models that involve muscle injury and/or wasting,” the authors conclude. “The end-goal of this approach would be to test new nutritional and pharmaceutical targets for treating muscle injury and associated inflammation.”

Resources

Advances in Bead-Based Biomarker Detection [Methods xMAP^® Issue]
Five Things We Learned from an xMAP^® Power User [Blog]
Getting Started with xMAP^® Technology [Video]
xMAP^® Cookbook to Design Your Own Assays [Download]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]

METHODS Special Issue: Multiplexing Protocol for Evaluating Biological Interactions with Nanoparticles

A new multiplexing protocol offers guidelines for measuring immunomodulatory effects of nanoparticles used in clinical applications

Nanoparticles have the potential to deliver more targeted therapies to the exact location in the body where they’re most needed. To do this, it is essential to understand how these foreign particles interact with a patient’s body. A recent publication in the Methods journal is a big step forward, offering a protocol for evaluating the body’s immune response to nanotechnology.

Scientists from Texas A&M University and Bio-Rad Laboratories designed parameters for evaluating the immunomodulatory effects of nano- and microparticles using multiplex biomarker analysis. To detect biomarkers of interest, the researchers utilized xMAP^® Technology from Luminex.

Considerations for monitoring the immunomodulatory effects of nanoparticles

According to the paper, the authors embarked on this project because “understanding the interactions of [particulate] materials with biological systems is crucial for the design of clinically-viable biomaterials,” they write. “The type and composition of nanomaterials plays a pivotal role in modulating the immune system, which may compromise therapeutic outcomes and can be life-threatening, [particularly] when the immunomodulation is unintentional.”

Multiplex techniques that allow for the analysis of as many as 500 biomarkers from a single sample would help address the need to characterize the effects of these particles, but certain challenges remain. For instance, the researchers note that “the adsorption of biomarkers on surfaces or within internal structures of nano- or microparticles has been explored to a lesser extent, although it can lead to biased conclusions and data misinterpretation.”

An empirical way to multiplex for large-scale biomarker analysis

With this protocol, the scientists aim to help other research teams looking to use multiplex technology to measure immunomodulatory effects of microparticles or nanoparticles by standardizing the techniques for both experiment preparation and analysis. The technique described is geared towards running 24 samples in triplicate on a 96-well plate, with appropriate standards and controls. The paper also includes precautions to help avoid artifacts, and to help with accurate data interpretation.

“The experimental details and precautions described [in the paper] allow for precise evaluation of biomarker expression in response to particulate materials, pharmaceuticals, and medical devices, and should be taken into careful consideration in pre-clinical and clinical studies, and other processes that involve the use of multiplexing techniques.”

Resources:

Advances in Bead-Based Biomarker Detection [Methods xMAP^® Issue]
Immunogenicity Profiling of Nanocarriers [xMAP^® Connect Webinar]
Getting Started with xMAP^® Technology [Video]
xMAP^® Cookbook to Design Your Own Assays [Download]
Browse 1,200+ Partner Kits with xMAP^® Kit Finder [Online Tool]

Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world.

References

Related Content

Webinar: Mouse Model Analysis Is Better with Multiplexing

Query hundreds of immunoassay targets, even with limited sample volume

Variability in Mouse Models

Generating Data with Minimal Biological Sample

Related Content

How to Choose an Assay Development Platform

The Luminex Team knows assay development. Check out some tips from our experts below.

Resources

3D Organoid Cultures Offer Clues to Heterogeneous Therapy Response in Cancer Patients

Luminex-powered DigiWest^® assays show significant intratumoral differences in response

Study Methods

Resources

MAGPIX^® Systems See New Life Through Equipment Donation Program

MilliporeSigma and Seeding Labs send gently used instruments to labs in need

Resources

METHODS Journal: A New Multiplexing Protocol Performs Protein and Gene Level Measurements on a Single Luminex Platform

Researchers demonstrate a high-throughput method for measuring mRNA and proteins using the Luminex xMAP^® Platform

Resources

Webinar: Fast, Economical Malaria Testing with xMAP^® Technology

Multiplex assay allows for detailed investigations of transmission and drug resistance

Developing Assays

Furthering Research

Resources

Webinar: Multiplex Serological Assay Developed to Identify Avian Influenza Subtypes

Rapid detection could help prevent transmission and reduce flock losses

Poultry Industry in The Netherlands

Resources

METHODS Special Issue: Multiplex Assays Enable Simultaneous Measurement of RNA and Proteins

A more comprehensive view sheds light on the biological response to muscle injury

Multiplex methods can do more with less

Resources

METHODS Special Issue: Multiplexing Protocol for Evaluating Biological Interactions with Nanoparticles

A new multiplexing protocol offers guidelines for measuring immunomodulatory effects of nanoparticles used in clinical applications

Considerations for monitoring the immunomodulatory effects of nanoparticles

An empirical way to multiplex for large-scale biomarker analysis

Resources:

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world.

References

Related Content

Query hundreds of immunoassay targets, even with limited sample volume

Variability in Mouse Models

Generating Data with Minimal Biological Sample

Related Content

The Luminex Team knows assay development. Check out some tips from our experts below.

Resources

Luminex-powered DigiWest® assays show significant intratumoral differences in response

Study Methods

Resources

MilliporeSigma and Seeding Labs send gently used instruments to labs in need

Resources

Researchers demonstrate a high-throughput method for measuring mRNA and proteins using the Luminex xMAP® Platform

Resources

Multiplex assay allows for detailed investigations of transmission and drug resistance

Developing Assays

Furthering Research

Resources

Rapid detection could help prevent transmission and reduce flock losses

Poultry Industry in The Netherlands

Resources

A more comprehensive view sheds light on the biological response to muscle injury

Multiplex methods can do more with less

Resources

A new multiplexing protocol offers guidelines for measuring immunomodulatory effects of nanoparticles used in clinical applications

Considerations for monitoring the immunomodulatory effects of nanoparticles

An empirical way to multiplex for large-scale biomarker analysis

Resources:

Follow us

Group

Our Solutions

Useful Links

Legal Information

Document Repository

Luminex-powered DigiWest^® assays show significant intratumoral differences in response

Researchers demonstrate a high-throughput method for measuring mRNA and proteins using the Luminex xMAP^® Platform